scientific data management

DNAnexus CEO Thomas Laur contends that AI drug discovery stalls not because of model limitations, but because scientific data infrastructure isn’t production-ready. The argument reframes where life sciences organizations should be investing. ECI Research data on engineering time allocation and AI scaling confidence supports the case.